Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Pelousse, Franz
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Is there potential for strontium ranelate in the management of osteoarthritis ?
Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet 377(9783), 2115-2126 (2011)
Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract. Res. Clin. Rheumatol. 20(1), 3-25 (2006)
Zhang LZ, Zheng HA, Jiang Y, Tu YH, Jiang PH, Yang AL. Mechanical and biologic link between cartilage and subchondral bone in osteoarthritis. Arthritis Care Res. 64(7), 960-967 (2012)
Abadie E, Ethgen D, Avouac B et al. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthr. Cartil. 12(4), 263-268 (2004)
Bruyere O, Burlet N, Delmas PD, Rizzoli R, Cooper C, Reginster JY. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet. Disord. 9, 165 (2008)
Marie PJ, Felsenberg D, Brandi ML. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int. 22(6), 1659-1667 (2011).
Saidak Z, Marie PJ. Strontium signaling: molecular mechanisms and therapeutic implications in osteoporosis. Pharmacol. Ther. 136(2), 216-226 (2012)
Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350(5), 459-468 (2004)
Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90(5), 2816-2822 (2005)
Reginster JY, Felsenberg D, Boonen S et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum. 58(6), 1687-1695 (2008)
Reginster JY, Kaufman JM, Goemaere S et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int. 23(3), 1115-1122 (2012)
Roux C, Reginster JY, Fechtenbaum J et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J. Bone Min. Res. 21(4), 536-542 (2006)
Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FR AX®. Osteoporos Int. 22(8), 2347-2355 (2011)
Kaufman JM, Audran M, Bianchi G et al. Efficacy and safety of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int. 23(Suppl. 2), S260 (2012)
Rizzoli R, Reginster JY, Boonen S et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif. Tissue Int. 89(2), 91-104 (2011)
Jonville-Bera AP, Autret-Leca E. [Adverse drug reactions of strontium ranelate (Protelos®) in France]. Presse Medicale 40(10), e453-e462 (2011)
Cooper C, Reginster JY, Cortet B et al. Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr. Med. Res. Opin. 28(3), 475-491 (2012)
Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv. Ther. 25(12), 1235-1256 (2008)
Kwan Tat S, Lajeunesse D, Pelletier JP, Martel-Pelletier J. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract. Res. Clin. Rheum. 24(1), 51-70 (2010)
Tat SK, Pelletier JP, Mineau F, Caron J, Martel-Pelletier J. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone 49(3), 559-567 (2011)
Saklatvala J. Inflammatory signaling in cartilage: MAPK and NF-kB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Curr. Drug Targets 8(2), 305-313 (2007)
Gulhan I, Bilgili S, Gunaydin R, Gulhan S, Posaci C. The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study. Arch. Gynecol. Obstet. 278(5), 437-441 (2008).
Montaseri A, Busch F, Mobasheri A et al. IGF-1 and PDGF-bb suppress IL-1beta-induced cartilage degradation through down-regulation of NF-kappaB signaling: involvement of Src/PI-3K/AKT pathway. PLoS ONE 6(12), e28663 (2011)
Renard E, Poree B, Chadjichristos C et al. Sox9/Sox6 and Sp1 are involved in the insulin-like growth factor-I-mediated upregulation of human type II collagen gene expression in articular chondrocytes. J. Mol. Med. (Berl.) 90(6), 649-666 (2012)
Henrotin Y, Labasse A, Zheng SX et al. Strontium ranelate increases cartilage matrix formation. J. Bone Min. Res. 16(2), 299-308 (2001)
Pelletier JP, Raynauld JP, Caron J et al. Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann. Rheum. Dis. 69(12), 2095-2101 (2010)
Pelletier JP, M K, Lajeunesse D, Al E. Strontium ranelate reduces the progression of invivo experimental dog osteoarthritis by inhibiting interleukin-1b and key proteases involved in cartilage degradation. Osteoporos Int. 23(Suppl. 2), S412 (2012).
Panahifar A, Maksymowych WP, Doschak MR. Potential mechanism of alendronate inhibition of osteophyte formation in the rat model of post-traumatic osteoarthritis: evaluation of elemental strontium as a molecular tracer of bone formation. Osteoarthr. Cartil. 20(7), 694-702 (2012)
Alexandersen P, Karsdal MA, Qvist P, Reginster JY, Christiansen C. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone 40(1), 218-222 (2007)
Alexandersen P, Karsdal MA, Byrjalsen I, Christiansen C. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric 14(2), 236-243 (2011).
Van Spil WE, Drossaers-Bakker KW, Lafeber FP. Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis. Ann. Rheum. Dis. 72(1), 29-36 (2013)
Bingham CO 3rd, Buckland-Wright JC, Garnero P et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 54(11), 3494-3507 (2006)
Lane NE, Nevitt MC, Genant HK, Hochberg MC. Reliability of new indices of radiographic osteoarthritis of the hand and hip and lumbar disc degeneration. J. Rheum. 20(11), 1911-1918 (1993)
Bruyere O, Delferriere D, Roux C et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann. Rheum. Dis. 67(3), 335-339 (2008)
Cooper C, Reginster JY, Chapurlat R et al. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr. Med. Res. Opin. 28(2), 231-239 (2012)
Namazi H. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr. Med. Res. Opin. 28(4), 609; author reply: 609-610 (2012)
Reginster JY, Badurski J, Bellamy N et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann. Rheum. Dis. 72(2), 179-186 (2013)
Reginster JY, Chapurlat R, Christiaensen C et al. Structure modifying effects of strontium ranelate in knee osteoarthritis. Osteoporos Int. 23(Suppl. 2), S58 (2012).
